The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the ...

Top-line results were announced from a phase 3 trial evaluating nerandomilast an oral, investigational phosphodiesterase 4B inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF).

Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week ...